{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:33:37Z","timestamp":1756308817080,"version":"3.30.0"},"reference-count":33,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14790","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:50:16Z","timestamp":1730807416000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum\u2011resistant recurrent ovarian cancer: A retrospective study"],"prefix":"10.3892","volume":"29","author":[{"given":"Huifen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, People's Hospital of Zhongshan City, Zhongshan, Guangdong 528403, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, People's Hospital of Zhongshan City, Zhongshan, Guangdong 528403, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muyou","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, People's Hospital of Zhongshan City, Zhongshan, Guangdong 528403, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"key20241202101929_b1-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"key":"key20241202101929_b2-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1002\/hsr2.936","article-title":"The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer","volume":"5","author":"Mazidimoradi","year":"2022","journal-title":"Health Sci Rep"},{"key":"key20241202101929_b3-ol-29-1-14790","first-page":"93","article-title":"Epidemiology and risk factors for ovarian cancer","volume":"22","author":"Ali","year":"2023","journal-title":"Prz Menopauzalny"},{"key":"key20241202101929_b4-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20241202101929_b5-ol-29-1-14790","first-page":"e30561","article-title":"Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer","volume":"14","author":"Zamwar","year":"2022","journal-title":"Cureus"},{"key":"key20241202101929_b6-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med"},{"key":"key20241202101929_b7-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"key20241202101929_b8-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14656566.2022.2112030","article-title":"Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer","volume":"24","author":"Singh","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"key20241202101929_b9-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","article-title":"Ovarian Cancer-Insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"key20241202101929_b10-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: A narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20241202101929_b11-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cancers16030641","article-title":"The poor prognosis of acquired secondary platinum resistance in ovarian cancer patients","volume":"16","author":"Elyashiv","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20241202101929_b12-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20241202101929_b13-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1147717","DOI":"10.3389\/fphar.2023.1147717","article-title":"Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine","volume":"14","author":"Mei","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20241202101929_b14-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamaoncol.2022.2253","article-title":"Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: The APPROVE randomized clinical trial","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20241202101929_b15-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA Open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20241202101929_b16-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/jcpt.13806","article-title":"Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study","volume":"47","author":"Geng","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"key20241202101929_b17-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: Ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"key20241202101929_b18-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20241202101929_b19-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20241202101929_b20-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"key20241202101929_b21-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: Consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20241202101929_b22-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2005.11.025","article-title":"Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer","volume":"102","author":"Le","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20241202101929_b23-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20241202101929_b24-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/15384101.2018.1471315","article-title":"Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel","volume":"17","author":"Qiu","year":"2018","journal-title":"Cell Cycle"},{"key":"key20241202101929_b25-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1593\/neo.101490","article-title":"Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases","volume":"13","author":"Volk","year":"2011","journal-title":"Neoplasia"},{"key":"key20241202101929_b26-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","article-title":"Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition","volume":"8","author":"Rapisarda","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"key20241202101929_b27-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1535-7163.MCT-15-0063","article-title":"Bevacizumab-Induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response","volume":"15","author":"Cesca","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20241202101929_b28-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/jog.15644","article-title":"Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer","volume":"49","author":"Yang","year":"2023","journal-title":"J Obstet Gynaecol Res"},{"key":"key20241202101929_b29-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.21873\/anticanres.16481","article-title":"Real-world efficacy and safety of bevacizumab for advanced or recurrent mullerian cancer: A Single-institutional experience","volume":"43","author":"Fukuda","year":"2023","journal-title":"Anticancer Res"},{"key":"key20241202101929_b30-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br J Cancer"},{"key":"key20241202101929_b31-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/diagnostics13061040","article-title":"Analysis of efficacy-to-safety ratio of angiogenesis-inhibitors based therapies in ovarian cancer: A systematic review and Meta-analysis","volume":"13","author":"Simion","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"key20241202101929_b32-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/jcm12052065","article-title":"Safety analysis of bevacizumab in ovarian cancer patients","volume":"12","author":"Wang","year":"2023","journal-title":"J Clin Med"},{"key":"key20241202101929_b33-ol-29-1-14790","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/annonc\/mds172","article-title":"Phase II study of bevacizumab with liposomal doxorubicin for patients with Platinum- and taxane-resistant ovarian cancer","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:19:37Z","timestamp":1733127577000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,5]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14790","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"article-number":"44"}}